Scarica l'app Stockscreener
4.27
10.91%
0.42
Precedente Chiudi:
$3.85
Aprire:
$3.92
Volume 24 ore:
462.20K
Relative Volume:
0.30
Capitalizzazione di mercato:
$52.35M
Reddito:
$128.60K
Utile/perdita netta:
$-4.60M
Rapporto P/E:
-12.20
EPS:
-0.35
Flusso di cassa netto:
$-3.74M
1 W Prestazione:
+12.37%
1M Prestazione:
+86.46%
6M Prestazione:
+322.77%
1 anno Prestazione:
+1,171%
Intervallo 1D:
$3.90
$4.27
Intervallo di 1 settimana:
$3.50
$4.27
Portata 52W:
$0.2528
$4.36
Nexalin Technology Inc Stock (NXL) Company Profile
Nome
Nexalin Technology Inc
Settore
Industria
Telefono
(832) 260-0222
Indirizzo
1776 YORKTOWN, HOUSTON
Confronta NXL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
4.27 | 52.35M | 128.60K | -4.60M | -3.74M | -0.35 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Nexalin Technology Inc Borsa (NXL) Ultime notizie
New Peer-Reviewed Publication Validates Nexalin’s Deep - GlobeNewswire
Nexalin's Brain Stimulation Tech Breakthrough Validated in Major Medical Journal | NXL Stock News - StockTitan
Nexalin Technology’s Strong Financial Position: No Defaults on Senior Securities - MSN
Nexalin Technology stock soars to all-time high of $4.07 - Investing.com
Nexalin Technology stock soars to all-time high of $4.07 By Investing.com - Investing.com UK
Nexalin Technology CEO Provides Letter to Shareholders - GlobeNewswire
Nexalin's Breakthrough: Alzheimer's Studies Show Promise, Secures Key Brain Tech Patent | NXL Stock News - StockTitan
Is Nexalin Technology (NASDAQ:NXL) In A Good Position To Invest In Growth? - Yahoo Finance
Nexalin Technology Inc (NXL) Quarterly 10-Q Report - Quartzy
Nexalin regains Nasdaq compliance with bid price rule By Investing.com - Investing.com Australia
Nexalin regains Nasdaq compliance with bid price rule - Investing.com India
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th - GlobeNewswire
Nexalin Technology : Regains Compliance with Nasdaq Continued Listing Requirements Form 8 K - Marketscreener.com
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements - The Manila Times
LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Nexalin technology's chief medical officer buys $1,095 in stock By Investing.com - Investing.com Canada
Nexalin technology's chief medical officer buys $1,095 in stock - Investing.com India
Significant Stock Increase For Nexalin (NXL) After Alzheimer’s Study Announcement - Stocks Telegraph
EXCLUSIVE: Nexalin Technology Says New Data Confirms Implantable Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients - AOL
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease - The Manila Times
Nexalin Technology Announces Landmark Study on Alzheimer's - GlobeNewswire
EXCLUSIVE: Nexalin Technology Says New Data Confirms Investigational Non-Invasive Neurostimulation Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients (UPDATED) - Benzinga
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Pre-Market Gains For Nexalin (NXL) Driven By Upcoming Clinical Trial - Stocks Telegraph
Nexalin trials Halo neurostimulation device in traumatic brain injury - Yahoo Finance
NXLNexalin Technology, Inc. Latest Stock News & Market Updates - StockTitan
Nexalin Technology Announces Planned Clinical Trial - GlobeNewswire
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership - The Bakersfield Californian
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA - StockTitan
Mixed results for Nexalin’s transcranial alternating current stimulation trial - Yahoo Finance
New Study Shows Nexalin’s Deep Intracranial Frequency - GlobeNewswire
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients - StockTitan
EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study - Benzinga
Nexalin Technology Inc [NXL] Investment Guide: What You Need to Know - Knox Daily
NXL: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs - GlobeNewswire
Nexalin Technology Inc’s latest rating changes from various analysts - Knox Daily
Maxim Group Initiates Coverage of Nexalin Technology (NXL) with Buy Recommendation - MSN
Nexalin Technology : HALO Global Regulatory Strategy Presentation - Marketscreener.com
Neta X Launch Date Revealed, Price Of IDR 400 Million? - VOI English
World of light and colour on its way to city centre - Newark Advertiser
NEXT Biometrics Expands in India with New Order - TipRanks
Business News | Content-sharing Startup Newzo Mobile App Gets Seed Funding by Concept PR Mumbai - LatestLY
Tetra Pak and NIFTEM Sign MoU to Advance Food Processing Innovation in India - ThePrint
Content-Sharing Startup Newzo Mobile App Gets Seed Funding By Concept PR Mumbai - Zee News
Nexalin Technology Welcomes New SVP Carolyn Shelton - TipRanks
This smallcap IT stock gave 191% returns in last one year, hits new all-time high; here's why - Upstox
Nexalin Technology Inc Azioni (NXL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nexalin Technology Inc Azioni (NXL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Owens David | Chief Medical Officer |
Aug 13 '24 |
Buy |
0.95 |
1,000 |
950 |
147,793 |
| Owens David | Chief Medical Officer |
Jun 28 '24 |
Buy |
1.75 |
1,000 |
1,750 |
146,793 |
| Owens David | Chief Medical Officer |
Jun 18 '24 |
Buy |
0.71 |
1,619 |
1,149 |
145,793 |
| Owens David | Chief Medical Officer |
Jun 10 '24 |
Buy |
0.64 |
3,000 |
1,920 |
144,174 |
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):